Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 26, 2025
Reporting Period: Event date February 26, 2025; Signed March 4, 2025.
Context: The filing discloses an amendment to the employment agreement of Judith Krandel, the Company's Chief Financial Officer, effective February 26, 2025.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation adjustments.
Material Changes
The primary material change is the amendment to the CFO's Letter Agreement dated July 28, 2023, which includes:
- Stock Option Grants: Two separate 10-year stock options granted under the 2024 Equity Incentive Plan:
- Option 1: 54,359 shares with time-based vesting (25% on first anniversary, remainder quarterly).
- Option 2: 58,961 shares with performance-based vesting tied to a strategic transaction increasing annual revenue by at least $4,000,000 (or 25% of projected revenue for years after 2025).
- Grant Date and Price: The grant date is the third business day after the filing of the 2024 Form 10-K; the exercise price will be the closing stock price on that date.
- Performance Bonus: Annual performance bonus target increased to 30% of annualized base salary.
- Termination Provisions: Full immediate vesting of all options (including 2025 Options) if employment is terminated for any reason other than "Cause."
Guidance, Outlook, and Risks
Management Commentary: The filing outlines specific revenue thresholds ($4,000,000 increase) required for the performance-based vesting of the second stock option grant, implying a strategic focus on revenue growth via transactions.
Risks and Contingencies: The vesting of the 58,961 share option is contingent upon the Board determining a strategic transaction is expected to meet specific revenue criteria. The filing notes that the complete Amendment will be filed as an exhibit to the Form 10-Q for the period ended March 31, 2025.
Investor Verification Checklist
- Verify the exact grant date and exercise price once the 2024 Form 10-K is filed.
- Review the full text of the Amendment in the upcoming Form 10-Q (Q1 2025) for detailed definitions of "Cause" and "Strategic Transaction."
- Monitor future filings for announcements of strategic transactions that may trigger the performance-based vesting of the 58,961 shares.
- Assess the impact of the increased bonus target (30%) on future compensation expenses.